Hodgkin's lymphoma Posts Page 2 on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Hodgkin lymphoma and thyroid cancer

Posted by on May 31, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined whether Hodgkin lymphoma survivors were more likely to develop more aggressive forms of thyroid cancer than the general population. The authors concluded that a history of Hodgkin lymphoma was not associated with aggressive subtypes or worse outcomes of thyroid cancer. Some background Hodgkin lymphoma survivors are at...

Read More

Is tandem stem cell transplantation effective in high risk relapsed/refractory Hodgkin lymphoma

Posted by on May 26, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effect of tandem stem cell transplantation (SCT) in patients with high-risk relapsed/refractory Hodgkin Lymphoma (HL). The main finding was that patients treated with tandem SCT had greater progression-free survival than those without. Some background A SCT involves the transfer of stem cells into the patient to...

Read More

What are the long-term outcomes for HL patients receiving plerixafor before a stem cell transplant?

Posted by on May 7, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the long-term outcomes of Hodgkin’s lymphoma (HL) patients who received plerixafor (Mozobil) to those who did not prior to autologous stem cell transplantation (autoSCT). This study concluded that plerixafor-treated patients had similar outcomes as patients who received conventional regimens. Some background...

Read More

Does high-dose GBM chemotherapy lead to better post-stem cell transplant outcomes compared to BEAM in refractory or relapsed Hodgkin’s lymphoma patients?

Posted by on May 3, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of primary refractory or relapsed Hodgkin’s lymphoma (HL) patients who received GBM (gemcitabine, busulfan, melphalan) or BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). This study concluded that GBM improved patient outcomes...

Read More

What are the long-term outcomes for HL patients who experience treatment failure after an autologous stem cell transplant?

Posted by on Apr 18, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study analyzed the survival outcomes of Hodgkin’s lymphoma (HL) patients who experience treatment failure after high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoSCT). This study concluded that a second stem cell transplant with or without brentuximab vedotin (Adcetris) may lead to better...

Read More

What are the outcomes for lymphoma patients who received TECAM chemotherapy before a stem cell transplant?

Posted by on Apr 18, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study analyzed data from patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) who received TECAM (etoposide, thiotepa, cytarabine, cyclophosphamide, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). The authors concluded that TECAM is an effective pre-autoSCT regimen for...

Read More

Can white blood cell count ratios help predict outcomes for newly diagnosed HL patients receiving PET2-mediated treatment?

Posted by on Apr 6, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the impact of white blood cell counts on the outcomes of newly diagnosed Hodgkin’s lymphoma (HL) patients receiving treatment mediated by PET2 (PET scanning after 2 cycles of chemotherapy). This study concluded that ratios of different types of white blood cells combined with PET2 can be a meaningful...

Read More

Does brentuximab vedotin improve stem cell transplant outcomes for classical Hodgkin’s lymphoma patients?

Posted by on Mar 30, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of classical Hodgkin’s lymphoma (cHL) patients who did or did not receive brentuximab vedotin (Adcetris) before allogeneic stem cell transplantation. This study concluded that pre-transplant brentuximab vedotin treatment does not lead to better post-transplant outcomes. Some background...

Read More